MTT Assay for Cytotoxicity Testing: Principle, Protocol, and Applications

The MTT assay is a gold-standard colorimetric method for measuring cell viability and cytotoxicity in vitro, based on the reduction of the yellow tetrazolium salt MTT into purple formazan crystals by metabolically active cells. Recognized by ISO 10993-5 as a reference technique for medical device biocompatibility evaluation, it is widely applied in pharmaceutical screening, chemical safety assessment, and biomaterials research. This article provides a comprehensive overview of the technical principle, testing samples, test items, experimental workflow, applications, and frequently asked questions related to the MTT cytotoxicity test.

Technical Overview

The MTT assay is a quantitative colorimetric technique used to evaluate cell viability and, conversely, cytotoxicity. MTT, or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, is a yellow, water-soluble tetrazolium salt. When it enters living cells, cellular dehydrogenase enzymes—principally mitochondrial succinate dehydrogenase and NAD(P)H-dependent oxidoreductases located in the mitochondria and cytoplasm—cleave the tetrazolium ring, converting MTT into insoluble purple formazan crystals that accumulate within the cells and around the cell membrane.

Because this enzymatic reduction depends directly on active cellular metabolism, the amount of formazan produced is proportional to the number of viable cells. After the incubation period, the formazan crystals are solubilized using a detergent such as dimethyl sulfoxide (DMSO), acidified isopropanol, or a solubilization buffer, producing a homogeneous purple solution. The optical density (OD) of this solution is then measured spectrophotometrically at a wavelength of approximately 570 nm, using a reference wavelength between 630 nm and 690 nm to correct for background absorbance.

Cell viability is typically calculated as the ratio of the corrected absorbance of treated cells to that of the untreated control, expressed as a percentage. According to ISO 10993-5, the international standard for in vitro cytotoxicity testing of medical devices, a test sample is considered cytotoxic when cell viability falls below 70% of the negative control. Key strengths of the MTT assay include its simplicity, high throughput compatibility with 96-well plates, low cost, and absence of radioactive isotopes. Its principal limitations are that it is an endpoint (destructive) assay and that certain colored or redox-active test substances may interfere with absorbance readings.

Testing Samples

Medical Devices and Biomaterials

Extracts or direct contact samples of medical devices, implants, wound dressings, dental materials, catheters, syringes, and tissue-engineering scaffolds are evaluated for cytotoxicity in accordance with ISO 10993-5 and ISO 10993-12. Test samples are prepared by extracting the material in culture medium with or without serum at 37°C for 24 to 72 hours.

Pharmaceutical Compounds

Small-molecule drugs, biologics, natural product extracts, and anticancer candidates are assayed as serial dilutions to establish dose–response relationships and determine the half-maximal inhibitory concentration (IC50).

Chemicals and Industrial Products

Industrial chemicals, surfactants, disinfectants, pesticides, and food-contact materials are tested for in vitro cytotoxicity as part of hazard identification and regulatory safety evaluation.

Cosmetics and Personal Care Products

Cosmetic ingredients and finished formulations are screened using the MTT assay as an alternative to animal testing, supporting safety assessments under regulations that restrict animal experimentation.

Nanomaterials and Advanced Materials

Nanoparticles, nanofibers, coatings, and drug-delivery carriers are assessed for potential cytotoxic effects, with appropriate controls to account for optical or chemical interference from the nanomaterial itself.

Testing Items

The MTT assay platform supports a range of quantitative cytotoxicity evaluations, including:

• Cell viability determination following exposure to a test substance or material extract
• Quantitative cytotoxicity grading in compliance with ISO 10993-5 requirements
• IC50 determination through full dose–response curve analysis
• Time-dependent cytotoxicity assessment at multiple exposure intervals (24, 48, and 72 hours)
• Cell proliferation inhibition analysis for antitumor and antimetastatic drug studies
• Comparative biocompatibility ranking of candidate materials or formulations
• Recovery and delayed cytotoxicity studies after removal of the test substance

Testing Methods

Standard Protocol

The MTT cytotoxicity test follows a well-established workflow that can be adapted to extraction (indirect contact), direct contact, or extract dilution formats. The standard procedure is outlined below:

• Cell seeding: Prepare a single-cell suspension and seed cells into a 96-well plate at a density of approximately 5,000 to 10,000 cells per well in 100 µL of complete culture medium. Incubate at 37°C in a humidified atmosphere with 5% CO2 for 18 to 24 hours to allow cell attachment.
• Treatment: Add test substances, material extracts, or serial dilutions of the test compound to the wells. Include a blank control (medium only), a negative control (untreated cells), and a positive control (cells treated with a known cytotoxic agent such as SDS or mitomycin C). Incubate for the designated exposure period, typically 24, 48, or 72 hours.
• MTT incubation: Add MTT solution (prepared from a 5 mg/mL phosphate-buffered saline stock) to each well to achieve a final concentration of approximately 0.5 mg/mL. Incubate for 2 to 4 hours at 37°C until purple formazan crystals become visible under a microscope.
• Formazan solubilization: Carefully remove the culture medium, taking care not to disturb the formazan deposit. Add 100 to 150 µL of DMSO or acidified isopropanol to each well and agitate on a plate shaker for 10 to 15 minutes until the crystals are fully dissolved.
• Absorbance measurement: Read the optical density at 570 nm using a 630 nm reference wavelength on a microplate reader.
• Data analysis: Calculate cell viability using the formula: Viability (%) = (OD_treated − OD_blank) / (OD_control − OD_blank) × 100%. Construct dose–response curves and calculate IC50 values using appropriate statistical or nonlinear regression software.

Commonly Used Cell Lines

Cell line selection depends on the intended application. L929 mouse fibroblasts are the reference cell line specified in ISO 10993-5 for medical device testing. Other frequently used lines include NIH/3T3 fibroblasts, HepG2 hepatocytes, HeLa and Hek293 epithelial cells, and tumor lines such as MCF-7, A549, and HCT116 for anticancer drug screening.

Quality Control Considerations

Reliable results require careful attention to cell density within the linear detection range, uniform seeding to avoid edge effects (using the outer wells as medium-only blanks), protection of MTT solution from light, and verification that test substances do not directly reduce MTT or absorb at the measurement wavelength. Replicate wells, typically six per condition, should be included to ensure statistical robustness.

Applications

The MTT assay is applied across academic research, industrial product development, and regulatory safety evaluation. Its principal application areas include:

• Pharmaceutical drug discovery, including high-throughput screening of compound libraries for cytotoxic or cytostatic activity
• Anticancer pharmacology, where the assay quantifies the tumor-selective potency of chemotherapeutic agents and natural products
• Medical device biocompatibility testing for regulatory submissions under ISO 10993-5 and related national standards
• Cosmetic and personal care product safety evaluation as an in vitro alternative to animal testing
• Nanotoxicology studies characterizing the biological effects of engineered nanomaterials
• Biomaterials and tissue engineering research for screening scaffold and hydrogel cytocompatibility
• Environmental toxicology, including assessment of water, soil, and air pollutant cytotoxicity
• Radiosensitizer and photodynamic therapy research for measuring treatment-induced loss of viability

FAQ

Why is MTT reduced only by living cells?

The reduction of MTT to formazan depends on active intracellular dehydrogenase enzymes and a continuous supply of reducing equivalents such as NADH and NADPH. Dead or metabolically inactive cells lose enzymatic activity and therefore cannot reduce MTT, so formazan production directly reflects the viable cell population.

What is the difference between the MTT assay and CCK-8, WST-1, MTS, or XTT assays?

MTT produces an insoluble formazan that requires a solubilization step, whereas WST-1, MTS, and XTT are newer tetrazolium salts that generate water-soluble formazan products and eliminate the dissolution step. CCK-8 uses WST-8 and is generally more sensitive and less toxic to cells, allowing repeated measurements. MTT remains the most economical and the standard method cited in ISO 10993-5.

What MTT concentration and incubation time should be used?

A final MTT concentration of 0.5 mg/mL with an incubation time of 2 to 4 hours at 37°C is standard. Incubation times that are too short underestimate viability, while excessive incubation can saturate the signal or stress the cells.

Can colored, opaque, or chemically reducing samples interfere with the assay?

Yes. Samples with intrinsic absorbance near 570 nm, or substances such as ascorbate and certain antioxidants that chemically reduce MTT in the absence of cells, can bias results. Appropriate sample-only blanks, interference controls, or orthogonal methods such as flow cytometry or neutral red uptake should be used to confirm findings.

What does an IC50 value represent?

The IC50 is the concentration of a test substance that reduces cell viability by 50% relative to the untreated control. It is derived from a fitted dose–response curve and serves as a key quantitative index for comparing the cytotoxic potency of different compounds.

What criteria define a cytotoxic result under ISO 10993-5?

Under the quantitative MTT method in ISO 10993-5, a test sample is considered cytotoxic if the viability of cells exposed to the sample extract is less than 70% of the negative control. Viability between 70% and 100% is generally regarded as non-cytotoxic, with intermediate values warranting further evaluation.

Why do edge wells sometimes show abnormal absorbance values?

Evaporation is more pronounced in the perimeter wells of a 96-well plate, which alters effective volumes and cell growth. Filling outer wells with sterile PBS or medium and using only inner wells for cell-based measurements effectively minimizes this edge effect.